Commentary: HCC With HCV and Treatment Comparisons for Unresectable HCC, August 2022July 28, 2022Hepatocellular Carcinoma
Beta-adrenergic receptor blocker use improves overall survival in HCCJuly 27, 2022Hepatocellular Carcinoma
Lenvatinib plus IDADEB-TACE tops lenvatinib monotherapy in advanced HCCJuly 27, 2022Hepatocellular Carcinoma
Meta-analysis supports the use of direct-acting antiviral therapy in HCV-related HCCJuly 27, 2022Hepatocellular Carcinoma
Statin use ties with lower HCC risk in dialysis patients with HBV or HCV monoinfectionJuly 27, 2022Hepatocellular Carcinoma
Lenvatinib combination therapy vs monotherapy against HCC: Real-world resultsJuly 27, 2022Hepatocellular Carcinoma
Lenvatinib combination therapy vs monotherapy against HCC: Real-world resultsJuly 27, 2022Hepatocellular Carcinoma
Advanced HCC: Radiotherapy+anti-PD1 a better therapeutic regimen than TACE+sorafenibJuly 27, 2022Hepatocellular Carcinoma
Sustained virologic response beneficial in patients with HCV-related HCC receiving nonsurgical managementJuly 27, 2022Hepatocellular Carcinoma
RFA and TACE: Equally effective bridging treatments in HCC patients awaiting liver transplantJuly 27, 2022Hepatocellular Carcinoma
First-line pembrolizumab: A promising therapeutic option in advanced HCCJuly 27, 2022Hepatocellular Carcinoma
Advanced HCC: First-line cabozantinib+atezolizumab in select patients shows promise but requires further studyJuly 27, 2022Hepatocellular Carcinoma
SBRT plus TACE better than monotherapy in HCC with portal vein tumor thrombusJune 23, 2022Hepatocellular Carcinoma
Unresectable HCC: Differential efficacy of atezolizumab plus bevacizumab according to hepatic function gradeJune 23, 2022Hepatocellular Carcinoma
